Coya Therapeutics Inc
COYA5.490USD
+0.190+3.58%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
91.92MMarket Cap
LossP/E TTM
More Details of Coya Therapeutics Inc Company
Coya Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in developing treatments focused on the biology and potential therapeutic advantages of regulatory T cells (Tregs) to target systemic inflammation and neuroinflammation. Its initial developmental programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases of high unmet medical need. Its diversified candidate pipeline includes both ex vivo and in vivo approaches. Its product candidate pipeline is based on its three therapeutic modalities. The product candidates utilizing its Treg-enhancing biologics are collectively referred to as the 300 Series. The product candidates utilizing its Treg-derived exosomes are collectively referred to as the 200 Series. The product candidates utilizing its autologous Treg cell therapy are collectively referred to as the 100 Series. The Company's 300 Series product candidates include COYA 301 and COYA 302.
Coya Therapeutics Inc Info
Ticker SymbolCOYA
Company nameCoya Therapeutics Inc
IPO dateDec 29, 2022
CEOSwaminathan (Arun)
Number of employees8
Security typeOrdinary Share
Fiscal year-endDec 29
Address5850 San Felipe St.
CityHOUSTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code77057
Phone8005878170
Websitehttps://www.coyatherapeutics.com/
Ticker SymbolCOYA
IPO dateDec 29, 2022
CEOSwaminathan (Arun)
Company Executives of Coya Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Dov A. Goldstein, M.D.
Dr. Dov A. Goldstein, M.D.
Independent Director
Independent Director
27.56K
+175.57%
Dr. Howard Berman, Ph.D.
Dr. Howard Berman, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
10.00K
--
Dr. Anabella Villalobos, Ph.D.
Dr. Anabella Villalobos, Ph.D.
Independent Director
Independent Director
10.00K
--
Dr. Fred Grossman
Dr. Fred Grossman
President, Chief Medical Officer
President, Chief Medical Officer
2.71K
--
Mr. Dieter Weinand
Mr. Dieter Weinand
Independent Director
Independent Director
--
--
Dr. Ann Louise Lee, Ph.D.
Dr. Ann Louise Lee, Ph.D.
Independent Director
Independent Director
--
--
Dr. Arun Swaminathan, Ph.D.
Dr. Arun Swaminathan, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Wilbur L. Ross
Mr. Wilbur L. Ross
Independent Director
Independent Director
--
--
Mr. David S. Snyder
Mr. David S. Snyder
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Dov A. Goldstein, M.D.
Dr. Dov A. Goldstein, M.D.
Independent Director
Independent Director
27.56K
+175.57%
Dr. Howard Berman, Ph.D.
Dr. Howard Berman, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
10.00K
--
Dr. Anabella Villalobos, Ph.D.
Dr. Anabella Villalobos, Ph.D.
Independent Director
Independent Director
10.00K
--
Dr. Fred Grossman
Dr. Fred Grossman
President, Chief Medical Officer
President, Chief Medical Officer
2.71K
--
Mr. Dieter Weinand
Mr. Dieter Weinand
Independent Director
Independent Director
--
--
Dr. Ann Louise Lee, Ph.D.
Dr. Ann Louise Lee, Ph.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Greenlight Capital, Inc.
7.87%
Bertex LLC
4.49%
The Vanguard Group, Inc.
4.00%
AIGH Capital Management, LLC.
3.95%
CM Management, LLC
1.43%
Other
78.26%
Shareholders
Shareholders
Proportion
Greenlight Capital, Inc.
7.87%
Bertex LLC
4.49%
The Vanguard Group, Inc.
4.00%
AIGH Capital Management, LLC.
3.95%
CM Management, LLC
1.43%
Other
78.26%
Shareholder Types
Shareholders
Proportion
Hedge Fund
8.62%
Investment Advisor
7.08%
Corporation
4.49%
Private Equity
3.95%
Investment Advisor/Hedge Fund
2.90%
Individual Investor
1.20%
Research Firm
0.20%
Other
71.56%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
61
4.75M
22.09%
--
2025Q3
62
4.77M
27.61%
+259.71K
2025Q2
56
4.51M
28.65%
-197.06K
2025Q1
47
4.69M
27.34%
+120.81K
2024Q4
44
4.47M
20.67%
+1.14M
2024Q3
34
3.34M
22.44%
+46.87K
2024Q2
32
3.29M
22.05%
-70.78K
2024Q1
29
3.36M
17.41%
+815.79K
2023Q4
23
2.57M
8.90%
+1.28M
2023Q3
20
1.28M
12.16%
+72.53K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Greenlight Capital, Inc.
1.65M
9.84%
--
--
Jun 30, 2025
Bertex LLC
939.34K
5.62%
--
--
May 06, 2025
The Vanguard Group, Inc.
840.47K
5.03%
--
--
Jun 30, 2025
AIGH Capital Management, LLC.
826.17K
4.94%
-64.88K
-7.28%
Jun 30, 2025
CM Management, LLC
200.00K
1.2%
--
--
Jun 30, 2025
Worth Venture Partners, LLC
279.45K
1.67%
-13.28K
-4.54%
Jun 30, 2025
Ross (Wilbur L Jr)
165.02K
0.99%
--
--
May 06, 2025
Geode Capital Management, L.L.C.
157.09K
0.94%
+1.26K
+0.81%
Jun 30, 2025
Dauntless Investment Group, LLC
51.09K
0.31%
-116.29K
-69.48%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
65.22K
0.39%
+2.01K
+3.18%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.02%
DFA Dimensional US Sustainability Core 1 ETF
0%
iShares Micro-Cap ETF
Proportion0.02%
DFA Dimensional US Sustainability Core 1 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Coya Therapeutics Inc?
The top five shareholders of Coya Therapeutics Inc are:
Greenlight Capital, Inc. holds 1.65M shares, accounting for 9.84% of the total shares.
Bertex LLC holds 939.34K shares, accounting for 5.62% of the total shares.
The Vanguard Group, Inc. holds 840.47K shares, accounting for 5.03% of the total shares.
AIGH Capital Management, LLC. holds 826.17K shares, accounting for 4.94% of the total shares.
CM Management, LLC holds 200.00K shares, accounting for 1.20% of the total shares.
Greenlight Capital, Inc. holds 1.65M shares, accounting for 9.84% of the total shares.
Bertex LLC holds 939.34K shares, accounting for 5.62% of the total shares.
The Vanguard Group, Inc. holds 840.47K shares, accounting for 5.03% of the total shares.
AIGH Capital Management, LLC. holds 826.17K shares, accounting for 4.94% of the total shares.
CM Management, LLC holds 200.00K shares, accounting for 1.20% of the total shares.
What are the top three shareholder types of Coya Therapeutics Inc?
The top three shareholder types of Coya Therapeutics Inc are:
Greenlight Capital, Inc.
Bertex LLC
The Vanguard Group, Inc.
Greenlight Capital, Inc.
Bertex LLC
The Vanguard Group, Inc.
How many institutions hold shares of Coya Therapeutics Inc (COYA)?
As of 2025Q4, 61 institutions hold shares of Coya Therapeutics Inc, with a combined market value of approximately 4.75M, accounting for 22.09% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -5.52%.
What is the biggest source of revenue for Coya Therapeutics Inc?
In --, the -- business generated the highest revenue for Coya Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
